Survival of 1,181 patients in a phase I clinic: The MD Anderson Clinical Center for targeted therapy experience

Clinical Cancer Research

Volumn 18, Issue 10, 2012, Pages 2922-2929

  Wheler, Jennifer ^a   Tsimberidou, Apostolia M ^a   Hong, David ^a   Naing, Aung ^a   Falchook, Gerald ^a   Piha Paul, Sarina ^a   Fu, Siqing ^a   Moulder, Stacy ^a   Stephen, Bettzy ^a   Wen, Sijin ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CYTOTOXIC AGENT; LACTATE DEHYDROGENASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; LIVER METASTASIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; THORAX CANCER; UROGENITAL TRACT CANCER; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASMS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861133847     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2217     Document Type: Article

References (22)

1. Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 2008;98:1029-33. (Pubitemid 351399798) (Pubitemid 351399798)
2. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996) (Pubitemid 13149996)
3. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87. (Pubitemid 26072233) (Pubitemid 26072233)
4. Bachelot T, Ray-Coquard I, Catimel G, Ardiet C, Guastalla JP, Dumortier A, et al. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 2000;11:151-6. (Pubitemid 30148727) (Pubitemid 30148727)
5. Arkenau HT, Olmos D, Ang JE, Barriuso J, Karavasilis V, Ashley S, et al. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer 2008;44:1536-40.
6. Roberts TG Jr, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004;292:2130-40. (Pubitemid 39435104) (Pubitemid 39435104)
7. Janisch L, Mick R, Schilsky RL, Vogelzang NJ, O'Brien S, Kut M, et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 1994;74:1965-73. (Pubitemid 24301862) (Pubitemid 24301862)
8. Yamamoto N, Tamura T, Yamamoto N, Fukuoka M, Saijo N. Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol 1999;15:737-41.
9. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, et al. Survival of patients in a phase 1 clinic: the M. D. Anderson Cancer Center experience. Cancer 2009;115:1091-9.
10. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, et al. Prospective validation of a prognostic score to improve patient selection for oncology Phase I trials. J Clin Oncol 2009;27:2692-6.
11. Penel N, Vanseymortier M, Bonneterre ME, Clisant S, Dansin E, Vendel Y, et al. Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs 2008;26:53-8.
12. Ray-Coquard I, Ghesquiere H, Bachelot T, Borg C, Biron P, Sebban C, et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001;85:816-22. (Pubitemid 33010546) (Pubitemid 33010546)
13. Seve P, Ray-Coquard I, Trillet-Lenoir V, Sawyer M, Hanson J, Broussolle C, et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer 2006;107:2698-705. (Pubitemid 44845626) (Pubitemid 44845626)
14. Coates RJ, Clark WS, Eley JW, Greenberg RS, Huguley CM Jr, Brown RL. Race, nutritional status, and survival from breast cancer. J Natl Cancer Inst 1990;82:1684-92.
15. Liu SA, Tsai WC, Wong YK, Lin JC, Poon CK, Chao SY, et al. Nutritional factors and survival of patients with oral cancer. Head Neck 2006;28: 998-1007.
16. Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, et al. Perceptions of cancer-patients and their physicians involved in Phase-I trials. J Clin Oncol 1995;13:1062-72.
17. Wheler J, Tsimberidou AM, Wen S, Naing A, Hong DS, Falchook GS, et al. Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The M. D. Anderson Cancer Center experience. In: American Society of Clinical Oncology Annual Meeting 2010. Chicago, IL: American Society of Clinical Oncology; 2010.
18. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, et al. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res 2010;16:4031-7.
19. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, et al. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab 2009;94:4423-32.
20. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010;16:1289-97.
21. Markman M. Assigning a cause for a particular outcome in oncology: a serious note of caution. Cancer 2008;113:668-70.
22. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol 2009;27:328-33.